1 Landmark Square
104 articles with Loxo Oncology
Biotech and pharma companies came roaring out of the gate on the first day of the annual J.P. Morgan Healthcare Conference with big deals, expansions and promises of growth and pipeline sustainability.
Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines through the addition of a marketed therapy and a pipeline of highly selective potential medicines for patients with genomically defined cancers.
Rowley Law PLLC is investigating potential claims against Loxo Oncology, Inc. and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Eli Lilly and Company
Eli Lilly and Company announced it was buying Loxo Oncology for $235 per share in cash, which comes to about $8 billion. The acquisition adds a lot of weight to Lilly’s oncology efforts.
It seems like every time we turned around this year, there was an exciting or—on a more visceral level, “Hey, that’s cool!” science story. Here’s a look at the top 9 really cool life science discoveries of the year, from outer space, to peanut allergies, to tortoise genomes.
US Bioservices Selected by Bayer and Its Collaboration Partner Loxo Oncology, Inc. to Dispense Vitrakvi® (larotrectinib)
New therapy approved to treat gene fusions across several different types of tumors
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
First treatment with a tumor-agnostic indication at the time of initial FDA approval
The U.S. Food and Drug Administration (FDA) gave the green light late Monday to Bayer oncology drug Vitrakvi, a first-of-its-kind TRK inhibitor, after late-stage clinical trial results showed a 75 percent overall response rate and 22 percent complete response rate across various solid tumors.
10/31/2018It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress
Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, and Bayer AG, Germany, today announced updated clinical data for larotrectinib, an investigational oral, selective, and CNS-active TRK inhibitor, in adult and pediatric patients with TRK fusion cancers.
Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types
Median duration of response (mDOR) in primary dataset not reached after follow-up of 17.6 months(1)
Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer from LIBRETTO-001 at the IASLC 19th World Conference on Lung Cancer
25/26 (96%) Responding Patients Remain on Therapy, With Median Follow-Up of 9.5 Months
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292
Loxo Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to LOXO-292
Recent studies in early diagnostics underline just how much focus medical technology companies are making on developing different modalities for very early cancer diagnosis. Here are just some recent examples.
Both “rare cancers” and “sub-populations of cancers” present a challenge to companies conducting clinical trials—finding enough patients for those trials.
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
Bayer announced today that the U.S.Food and Drug Administration (FDA) has accepted the New Drug Application (NDA).
FDA Accepts NDAs and Grants Priority Review to Loxo Oncology, Astellas Pharma and Catalyst Pharma...
5/29/2018Following the long holiday weekend, three pharma companies began the week with good news as the U.S. Food and Drug Administration awarded their therapies with Priority Review Status.
Loxo Oncology shares climbed 19 percent after data for its cancer drug LOXO-292 was released.
Agreement Leverages Veracyte’s New Afirma Xpression Atlas Platform